July 18th 2025
Treatment with casdatifan in combination with cabozantinib produced responses and was safe in patients with pretreated clear cell renal cell carcinoma.
High levels of CD163-positive TAMs and exhausted CD8-positive TILs could potentially affect efficacy results in metastatic RCC by reprogramming TAMs.
KIM-1 levels have shown the ability to predict therapeutic benefit in patients with renal cell carcinoma.
Ritesh R. Kotecha, MD, discusses the rationale for targeting ENPP3 in clear cell renal cell carcinoma.
Findings from the KEYNOTE-B61 trial demonstrate antitumor activity across histologic subtypes, including those with papillary and chromophobe disease.
Karie Danielle Keera Runcie, MD, discusses treatment challenges after progression on adjuvant therapy and the potential role for zanzalintinib in renal cell carcinoma.
Treatment with belzutifan increased the time without progression or toxicity vs everolimus in patients with advanced RCC.
Metastasis-directed radiotherapy without systemic therapy demonstrated an improved safety profile vs immunotherapy and tyrosine kinase inhibitors.
July 17th 2025
Thomas Powles, MD, discusses results from a Q-TWiST analysis of belzutifan vs everolimus in previously treated advanced renal cell carcinoma.
Marc Machaalani, MD, discusses retrospective findings from a multi-platform analysis evaluating circulating KIM-1 as a biomarker in metastatic RCC.
David A. Braun, MD, PhD, discusses findings from a study of personalized neoantigen vaccines in patients with high-risk, resectable ccRCC.
Research supports the use of novel CAR T-cell therapy targeting CAIX and CD70 for the treatment of patients with advanced ccRCC.
July 12th 2024
Belzutifan generated superior efficacy and safety outcomes vs everolimus across prespecified subgroups of patients with previously treated advanced ccRCC.
Treatment with single-agent abemaciclib (Verzenio) did not demonstrate clinically meaningful activity in heavily treated patients with metastatic clear cell renal cell carcinoma.
Fianlimab plus cemiplimab produced durable responses in heavily pretreated advanced clear cell renal cell carcinoma.
Most patients included in the post-hoc pooled analysis who were treated with belzutifan experienced an all-cause adverse effect.
Karl Semaan, MD, MSc, discusses the utility of liquid biopsy epigenomic profiling for the detection of sarcomatoid renal cell carcinoma.
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib in clear cell renal cell carcinoma.
Laurence Albiges, MD, PhD, discusses research evaluating treatments for subtypes of non–clear cell renal cell carcinoma.
Real-world treatment patterns demonstrated that similar OS outcomes occurred for patients with renal cell carcinoma who received TKI- and immunotherapy-based regimens.
